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Abstract
Setting
40 primary health clinics (PHCs) in four provinces in South Africa, June 2012 –February
2013.
Objective
To determine whether health care worker (HCW) practice in investigating people with TB
symptoms was altered when the initial test for TB was changed from smear microscopy to
Xpert MTB/RIF.
Design
Cross-sectional substudy at clinics participating in a pragmatic cluster randomised trial,
Xpert for TB: Evaluating a New Diagnostic "XTEND", which evaluated the effect of Xpert
MTB/RIF implementation in South Africa.
Methods
Consecutive adults exiting PHCs reporting at least one TB symptom (defined as any of
cough, weight loss, night sweats and fever) were enrolled. The main outcome was the pro-
portion who self-reported having sputum requested by HCW during the clinic encounter just
completed.
Results
3604 adults exiting PHCs (1676 in Xpert arm, 1928 in microscopy arm) were enrolled
(median age 38 years, 71.4% female, 38.8% reported being HIV-positive, 70% reported
cough). For 1267 participants (35.2%) the main reason for attending the clinic was TB
symptom(s).
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Overall 2130/3604 (59.1%) said they reported their symptom(s) to HCW. 22.7% (818/
3604) reported having been asked to give sputum for TB investigation. Though participants
in the Xpert vs. microscopy arm were more likely to have sputum requested by HCW, this
was not significantly different: overall (26.0% [436/1676] vs 19.8% [382/1928]; adjusted
prevalence ratio [aPR] 1.31, [95% CI 0.78–2.20]) and when restricted to those presenting at
clinics due to symptoms (49.1% [260/530] vs 29.9% [220/737]; aPR 1.38 [0.89–2.13]) and
those reporting being HIV-positive (29.4% [190/647] vs 20.8% [156/749]; aPR 1.38[0.88–
2.16]).
Those attending clinic due to TB symptoms, were more likely to have sputum requested
if they had increasing number of symptoms; longer duration of cough, unintentional weight
loss and night sweats and if they reported symptoms to HCW.
Conclusions
A large proportion of people exiting PHCs reporting TB symptoms did not get tested. Imple-
mentation of Xpert MTB/RIF did not substantially change the probability of testing for TB.
Better systems are needed to ensure that opportunities to identify active TB among PHC
attendees are not missed.
Background
The burden of tuberculosis (TB) remains high in South Africa, with an estimated prevalence of
715 per 100 000 population in 2013 [1]. Despite better TB diagnostics, many people with TB
remain undiagnosed or diagnosed but not started on appropriate treatment [1]. Control of TB
in these high prevalence settings depends on early diagnosis and prompt initiation of appropri-
ate treatment.
To reduce the burden of TB the World Health Organization (WHO) recommends intensi-
fied case finding (ICF) for TB among human immunodeficiency virus (HIV) infected persons
[2, 3] and has also been recommended for all clinic attendees, regardless of HIV status [4].
Screening for TB is also an important step in triaging potentially infectious individuals at
health facilities as part of infection control [5].
The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA), an automated nucleic acid amplifica-
tion test that can detect bothMycobacterium tuberculosis [MTB] and rifampicin resistance, has
very good sensitivity and specificity [6, 7] and can contribute to improving case finding. Since
2011, South Africa has rolled out Xpert MTB/RIF as the first-line sputum test for diagnosis of
TB across the country, replacing smear microscopy. Embedded within this roll out was the
XTEND trial, an evaluation of the effect of Xpert MTB/RIF implementation on patient-rele-
vant outcomes [8]. The trial was a pragmatic, two arm, parallel, cluster-randomised trial where
a cluster was defined as a laboratory and two clinics served by, but not co-located with, the lab-
oratory. The primary outcome, mortality, was determined at six months among clinic attend-
ees being investigated for TB.
Given that the outcomes of testing with Xpert MTB/RIF are critically dependent on the
characteristics of the population having sputum sent for investigation, we needed to under-
stand whether the process of implementing Xpert MTB/RIF changed health care worker
(HCW) behaviour in requesting sputum for laboratory investigation. We reasoned that intro-
duction of a new TB diagnostic test widely publicised as more sensitive could potentially
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encourage HCW to test more people for TB. Alternatively, knowledge that the new test was
more expensive could influence HCW to ration its use. Therefore within the XTEND study, in
this exit interview substudy, we aimed to determine, among adults exiting primary health clin-
ics (PHCs) who reported at least one TB symptom, i) the proportion having sputum requested
by an HCW by study arm and ii) factors associated with having sputum requested.
Methods
Ethics Statement
This study was approved by the ethics committees of the University of the Witwatersrand; the
University of Cape Town, the London School of Hygiene and Tropical Medicine; and the
World Health Organization. All consenting participants gave written consent or, for illiterate
participants, witnessed verbal consent. For illiterate participants, there was an impartial witness
present during the consenting process, who then signed the relevant witness section of the con-
sent form. Both ethics committees approved the consent form, including the section on the use
of witnessed oral consent for illiterate participants, at the beginning of the study. Principles
expressed in the Declaration of Helsinki were followed in the conduct of this research.
Study Design: The XTEND Study
In the XTEND study, a cluster was defined as a laboratory and two (PHCs) served by that labo-
ratory. Laboratories were identified from four provinces, Gauteng, Mpumalanga, Free State
and Eastern Cape provinces, and randomised to Xpert or microscopy as previously described
[8].
Study Design: Exit Interview Substudy
This was a cross-sectional study among adults exiting clinics at all 40 PHCs in both Xpert and
microscopy arms.
Study Population
Consecutive adults (18 years) leaving PHCs were screened for the exit interview substudy. A
consecutive sample of those who reported to the research team at least one symptom suggestive
of TB predefined according to WHO criteria, (i.e. cough24 hours, night sweats, weight loss
and fever, hereafter referred to as “TB symptoms”) [2] were invited to take part in the study
and enrolled if they were attending the clinic for personal health issues rather than accompa-
nying a relative or friend. We excluded participants who had had sputum sent for TB investiga-
tions prior to the current visit or were already on TB treatment.
Study Procedures
Data on demographics, additional information on TB symptoms and other clinical data rele-
vant to TB were collected through an interview. Participants were also asked if they had had
sputum requested by a HCW at that visit, and if sputum had not been requested, they were
referred back to the clinic staff for appropriate investigations.
Study Outcomes
The main outcome was the proportion of participants who had sputum requested by a HCW.
Sensitivity analyses were conducted among three subgroups: those who reported that (i) their
main reason for attending the clinic was because they had at least one TB symptom (ii) they
Missed Opportunities for TB Investigation
PLOS ONE | DOI:10.1371/journal.pone.0138149 September 18, 2015 3 / 11
had reported a TB symptom to HCW; iii) self-reported cough and reported cough to HCW
(iv) they were HIV-positive.
Data Management
All data including participant identifiers and enrolment questionnaire were collected using a
custom designed data collection application on a smart phone as previously described [8].
Completed forms were submitted in an encrypted format via the cell phone network into a cen-
tral repository database maintained at a contracted software company.
Statistical Considerations
We assumed 10 clusters per arm (as dictated by the sample size for the XTEND study). We
estimated that among clinic attendees reporting TB symptoms in the microscopy arm, 25%
would have sputum requested by a HCW. With 200 clinic attendees per cluster and a coeffi-
cient of variation of 0.25, we estimated there would be 90% power to detect an absolute reduc-
tion greater than 10% or increase of at least 15% in TB testing in the Xpert arm.
The statistical analysis was conducted using STATA (version 12, StataCorp LP, College Sta-
tion, Texas). The effect of study arm on the outcome for the main and sensitivity analyses used
methods appropriate to the trial design with a small number of clusters [9], including adjust-
ment for individual level baseline factors showing imbalance by study arm.
Analysis of Factors Associated with Having Sputum Requested by HCW
Among participants whose main reason for attending the clinic was TB symptoms, a risk factor
analysis was conducted using logistic regression with random effects to identify individual level
factors associated with having sputum requested by HCW. The random effects model took
into account clustering of patients within clinics. Factors with evidence of an association with
the primary outcome (p value<0.05) in the univariable analysis were included in the multivar-
iable model and adjusted odd ratios (aOR) and 95% confidence intervals (CIs) estimated. A pri-
ori, sex and age group were included in the fully-adjusted model.
Results
Participants
From June 2012 to February 2013 we screened 8104 adults upon exit from PHCs of whom
4098 were eligible and offered enrolment (Fig 1). 134 declined enrolment and 3964 were
enrolled. A further 360 participants were subsequently withdrawn; one entire cluster where the
study protocol was not adhered to (n = 197), participants who were either already on TB treat-
ment or were being investigated for TB prior to the index visit (n = 115), participants enrolled
in error either because their age could not be confirmed (n = 30) or were<18 years of age
(n = 14) and four participants who did not complete the survey, leaving 3604 participants
(1676 in the Xpert arm, 1928 in the microscopy arm) in the analysis.
Among these 3604 participants, the median age was 38 years, and 71.4% were female. Of the
2610 (72.4%) participants willing to share their HIV status 1398 (38.8%) reported being HIV
positive and of these, 908 (64.9%) were on antiretroviral therapy (ART) (Table 1). Among all
3604 participants, 70.6% and 30.8% reported cough and fever respectively with similar propor-
tions reporting weight loss and night sweats (42.1% and 41.6% respectively). For 1267 partici-
pants (35.2%) the main reason for attending the clinic was due to having at least one TB
symptom (Table 1). Overall 2130/3604 (59.1%) had reported TB symptom(s) to HCW. Gener-
ally the characteristics were balanced by study arm except that participants in the Xpert arm
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Fig 1. Participant flow for the exit interview substudy. Legend: *Participant enrolment errors, Xpert arm: did not complete survey n = 2; underage n = 10;
attending clinic for TB care n = 66. **Participant enrolment errors, Microscopy arm: did not complete survey n = 2; underage n = 4; attending clinic for TB care
n = 49.
doi:10.1371/journal.pone.0138149.g001
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Table 1. Characteristics of participants by arm.
Xpert Microscopy
(n = 1676) (n = 1928)
Age in years median (IQR) 35 (27–48) 41 (30–53)
Sex Female % (n) 73.3% (1228) 69.8% (1345)
Country of birth South Africa % (n) 93.0% (1558) 95.5% (1842)
Ethnicity Black % (n) 98.7% (1654) 96.6% (1863)
Marital status Single % (n) 52.3% (877) 55.1% (1063)
Education Level Grade 0–7 % (n) 34.7% (582) 36.4% (702)
Grade 8–11 % (n) 42.3% (709) 39.4% (760)
Grade 12 % (n) 19.9% (334) 20.6% (398)
Post-secondary % (n) 3.0% (51) 3.5% (68)
Dwelling Concrete % (n) 58.4% (979) 74.7% (1440)
Traditional % (n) 27.4% (460) 11.8% (228)
Informal % (n) 8.5% (142) 8.5% (164)
On property/backroom % (n) 5.7% (95) 5.0% (96)
Symptoms reported
Cough Yes % (n) 68.3% (1144) 72.6% (1399)
Night sweats Yes % (n) 39.9% (669) 43.0% (829)
Weight loss Yes % (n) 41.1% (688) 43.2% (832)
Fever Yes % (n) 22.8% (382) 37.8% (729)
Total number of symptoms1 1 % (n) 50.8% (851) 38.9% (749)
2 % (n) 30.3% (508) 34.1% (658)
3 % (n) 15.0% (252) 18.7% (360)
4 % (n) 3.9% (65) 8.4% (161)
Symptoms duration
Cough None % (n) 31.7% (532) 27.4% (528)
= <2weeks % (n) 44.4% (744) 50.6% (976)
>2weeks % (n) 23.9% (400) 22.0% (424)
Night sweats None % (n) 60.1% (1007) 57.0% (1099)
= <2weeks % (n) 15.5% (259) 24.3% (468)
>2weeks % (n) 24.5% (410) 18.7% (361)
Weight loss None % (n) 58.9% (988) 56.9% (1096)
= <2weeks % (n) 9.3% (155) 16.3% (315)
>2weeks % (n) 31.8% (533) 26.8% (517)
Fever None % (n) 77.2% (1294) 62.2% (1199)
= <2weeks % (n) 17.1% (286) 27.4% (528)
>2weeks % (n) 5.7% (96) 10.4% (201)
Previous tuberculosis Yes % (n) 12.7% (213) 17.0% (327)
HIV status, self-report2 Negative %(n) 34.1% (572) 31.7% (611)
Positive % (n) 16.4% (275) 11.8% (227)
Positive on ART % (n) 22.2% (372) 27.1% (523)
Unknown % (n) 27.3% (457) 29.4% (567)
Main reason for visit TB symptoms % (n) 31.6% (530) 38.2% (737)
HIV care % (n) 21.5% (360) 22.7% (437)
HIV test % (n) 5.4% (91) 3.9% (76)
General/chronic3 % (n) 17.8% (298) 19.8% (382)
ANC % (n) 5.9% (99) 3.0% (58)
Other % (n) 17.8% (298) 12.3% (238)
Reported TB symptoms to health care worker Yes % (n) 54.0% (905) 63.5% (1225)
1Total number of symptoms based on current cough, night sweats, fever and weight loss; TB = tuberculosis; ART = antiretroviral therapy; ANC = antenatal
clinic attendance
2 Percentage HIV positive out of those willing to share HIV status 52.6% (647/1232) and 54.5% (749/1375) in the Xpert and microscopy arms,
respectively.
3Attending clinic for other routine chronic disease follow-up, such as diabetes and hypertension
doi:10.1371/journal.pone.0138149.t001
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were less likely to have attended the clinic because of TB symptoms, and, if HIV positive, were
less likely to be on (ART).
Effect of Xpert MTB/RIF on Study Outcomes
Overall 22.7% of participants (818) self-reported being requested to give sputum for TB investi-
gation: 26.0% (436/1676) in Xpert arm compared to 19.8% (382/1928) in the control arm, giv-
ing a prevalence ratio [PR] of 1.24 (95% CI 0.65–2.36; p = 0.49). After adjusting for baseline
imbalance there was a 31% increase in the percentage of participants having sputum requested
in the Xpert compared to control arm (adjusted PR 1.31, 95% CI 0.78–2.20, p = 0.28, Table 2).
Sensitivity Analyses
Restricting to those whose main reason for attending the clinic was because they had TB symp-
toms (n = 1267), 37.9% had sputum requested by HCW and was higher in Xpert compared to
control arm (49.1%, 260/530 vs 29.9%, 220/737), though the CI were wide (adjusted PR 1.38,
95% CI 0.89–2.13, p = 0.14, Table 2).
Among a subgroup who said that they reported TB symptoms to HCWs (n = 2130), 42.4%
(384/905) and 28.2% (345/1225) had sputum requested in the Xpert and control arms respec-
tively, giving an adjusted PR of 1.47 (95% CI 0.99–2.16, p = 0.05). Restricting to those who self-
reported cough and reported having a cough to health care workers (n = 1624), 49.6% (338/
681) and 31.7% (299/943) had sputum requested in the Xpert and control arms respectively,
giving an adjusted PR of 1.53 (95% CI 1.01–2.29, p = 0.04).
Of the 1397 participants who reported living with HIV, 29.4% (190/647) vs. 20.8% (156/
749) had sputum requested in Xpert and control arms respectively. After adjusting for age, gen-
der, cough duration, duration of night sweats, number of TB symptoms, reason for visiting
clinic and whether on ART, the adjusted PR was 1.38 (95% CI 0.88–2.16, p = 0.15, Table 2).
Table 2. Effect of Xpert on primary and secondary outcomes.
Primary outcome
Xpert Microscopy Prevalence ratio (95% CI), p-value
Sputum
requested n/N
%* Sputum
requested n/N
%* Unadjusted Adjusted
Proportion having sputum requested by HCW
(n = 3604)
436/1676 26.0% 382/1928 19.8% 1.24 (0.65–2.36),
p = 0.49
1.31 (0.78–2.20),
p = 0.28
Sensitivity analyses
Main reason for attending clinic was TB
symptoms (n = 1267)1
260/530 49.1% 220/737 29.9% 1.45 (0.87–2.40),
p = 0.14
1.38 (0.89–2.13),
p = 0.14
Reported TB symptoms to health care worker
(n = 2130)2
384/905 42.4% 345/1225 28.2% 1.56 (1.00–2.43),
p = 0.05
1.46 (0.99–2.16),
p = 0.05
Self-reported cough and reported cough to
health care workers2 (n = 1624)
338/681 49.6% 299/943 31.7% 1.62 (1.03–2.52),
p = 0.04
1.53 (1.02–2.29),
p = 0.04
Living with HIV (n = 1396)2 190/647 29.4% 156/749 20.8% 1.38 (0.74–2.57),
p = 0.29
1.38 (0.88–2.16),
p = 0.15
CI = conﬁdence interval
*summary ignores cluster
1Adjusted for age group, gender, duration of cough, duration of night sweats, number of WHO TB symptoms, and HIV status with ART
2Adjusted for age group, gender, duration of cough, duration of night sweats, number of WHO TB symptoms, reason for attending clinic and HIV status
with ART
doi:10.1371/journal.pone.0138149.t002
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Factors Associated with Having Sputum Requested by HCW
Among those attending clinic because of TB symptoms (n = 1267), individual level factors
associated with higher odds of having sputum requested by HCW included being male (aOR
1.49, 95% CI 1.13–1.97), self-reported HIV positive status and not on ART versus HIV negative
(aOR 2.58, 95% CI 1.69–3.92) and if they informed HCW of symptoms (aOR 4.81, 95% CI
2.88–8.03). Participants reporting increasing number of symptoms were more likely to have
sputum requested (2 vs 1, Table 3). Similarly the longer the duration of cough, night sweats
and weight loss (2 weeks vs2 weeks) the more likely the participants were to have sputum
requested by HCW (Table 3).
Discussion
Our data suggests opportunities are being missed to identify TB cases at PHCs where people
present with symptoms suggestive of TB. Our findings show that a large proportion of clinic
attendees reporting at least one TB symptom did not have sputum taken for further TB investiga-
tions in both the Xpert MTB/RIF and microscopy arm. In this study from a high HIV and TB
burden setting where Xpert MTB/RIF assay has been adopted as the initial test for TB, the imple-
mentation of Xpert did not change HCWTB investigation practices. Implementation of the new
test, Xpert MTB/RIF resulted in a modest increase in the proportion of symptomatic patients
having sputum requested for TB investigations. There was some evidence of an effect among
those who reported TB symptoms to the HCWwith a 47% increase in those having sputum
requested in the Xpert arm. Given that Xpert MTB/RIF would have been perceived as an expen-
sive test, HCWs appeared not to have rationed its use at these primary health care clinics.
Having sputum collected for TB investigation among persons with presumed TB is critical
step in the continuum of care. Among those who reported a cough to a HCW, less than half
had sputum collected for TB tests. This despite South African guidelines for HIV-positive per-
sons [10] and TB infection control advising screening of all persons for TB symptoms at entry
to health care facilities [11]. More importantly, these findings suggest failure to request TB
tests, even among people reporting a cough to HCWs. Furthermore this also represents poor
infection control practice as these potentially infectious persons would ideally have been tri-
aged on entry to minimise transmission to other clinic clients. Other data suggests that active
screening may increase the number of cases found and decrease the time to detection [12].
Our data show that one of the strongest factors associated with having sputum sent for TB
investigations was if people reported a symptom to the HCW.We did not collect data on why
patients did not report symptoms to HCW but it would seem reasonable to suggest that there
could be activities at facilities to educate patients about TB symptoms, encourage them to spe-
cifically report them and ask for a test for TB. Other studies reporting missed opportunities for
diagnosing TB also noted the importance of educating people attending health services about
TB symptoms and testing [4]. Interestingly those who reported more symptoms and symptoms
of longer duration, were more likely to have sputum requested. As HCWs were not interviewed
in this study, we cannot infer why they were more likely to request sputum in such cases but it
would seem plausible that the recommendations for TB screening are not being adhered to.
TB screening is recommended for HIV-positive individuals at every clinic visit [13]. In our
study HIV-positive individuals were more likely to be investigated for TB if they were not on
ART. Screening for TB among HIV-positive individuals is important regardless of whether
they are receiving ART or not and also provides an opportunity to evaluate patients for eligibil-
ity to start isoniazid preventive therapy.
Our study has limitations; we enrolled people exiting PHCs and depended on self-report by
the participants to determine whether or not a sputum sample was requested. This information
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was not verified by clinic record review. Among those screened for eligibility to the study, the
proportion of participants reporting TB symptoms (50%) seems very high and we could not
verify if study staff at times pre-screened participants. Study staff were trained continuously
during the study and monitoring visits conducted.
The proportion having sputum requested was low in both Xpert and microscopy arms even
among those whose main reason for attending clinic was because of TB symptoms. In settings
Table 3. Factors associated with having sputum requested for TB investigations among clients attending clinic because of symptoms suggestive
of TB (Xpert andmicroscopy arms combined, n = 1267).
Total Sputum requested by HCW Unadjusted OR
(95% CI)
P value Adjusted OR* (95% CI) P value
n (row %)
All participants 1267 480 (37.9)
Age, years 0.14 0.37
18–29.9 380 139 (36.6) 1 1
30–34.9 187 71 (38.0) 1.17 (0.79–1.75) 0.93 (0.60–1.43)
35–39.9 136 61 (44.9) 1.41 (0.91–2.19) 1.17 (0.72–1.89)
40–49.9 253 108 (42.7) 1.54 (1.07–2.20) 1.23 (0.83–1.81)
50 311 101 (32.5) 1.06 (0.75–1.51) 0.82 (0.57–1.21)
Gender 0.0005 0.0051
Female 813 273 (33.6) 1 1
Male 454 207 (45.6) 1.58 (1.22- 2.04) 1.49 (1.13–1.97)
Cough duration <0.0001 <0.0001
No cough 220 41 (18.6) 1 1
2 weeks 656 236 (36.0) 3.04 (2.02–4.58) 3.00 (1.94–4.63)
>2 weeks 391 203 (51.9) 5.08 (3.30–7.81) 4.63 (2.95–7.28)
Duration of night sweats <0.0001 0.0001
None 697 216 (31.0) 1 1
2 weeks 299 138 (46.2) 2.05 (1.51–2.78) 1.92 (1.39–2.65)
>2 weeks 271 126 (46.5) 1.73 (1.25–2.88) 1.62 (1.12–2.34)
Weight loss duration 0.0024
None 700 229 (32.7) 1
2 weeks 189 86 (45.5) 1.80 (1.26–2.58)
>2 weeks 378 165 (43.7) 1.39 (1.04–1.86)
Number of WHO symptoms <0.0001
One 419 111 (26.5) 1
Two 430 166 (38.6) 1.96 (1.42–2.69)
Three 295 137 (46.4) 2.73 (1.92–3.89)
Four 123 66 (53.7) 3.83 (2.39–6.12)
HIV status <0.0001 0.0001
HIV negative 458 144 (31.4) 1 1
HIV +/on ART 167 56 (33.5) 1.27 (0.84–1.91) 1.22 (0.78–1.92)
HIV +/not on ART 181 111 (61.3) 2.83 (1.91–4.19) 2.58 (1.69–3.92)
HIV unknown 461 169 (36.7) 1.18 (0.87–1.60) 1.18 (0.86–1.63)
Informed health worker of symptoms <0.0001 <0.0001
No 188 22 (11.7) 1 1
Yes 1079 458 (42.5) 5.84 (3.56–9.56) 4.81 (2.88–8.03)
* controlling for clinic using a random effects model
doi:10.1371/journal.pone.0138149.t003
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of high TB prevalence, undetected TB is frequently identified when intensified screening is
done in household contacts [14,15] and newly diagnosed HIV-positive individuals attending
HIV testing and counselling [16, 17,18]. Not investigating people presenting at clinics with
symptoms suggestive of TB presents a missed opportunity for diagnosing TB. In South Africa
where HIV is also prevalent, with services integrated at primary health care level, investigating
clinic attendees for TB also provides an opportunity for raising awareness of TB symptoms and
linkage to HIV testing and care services.
Conclusions
In conclusion many people who have at least one TB symptom are not being tested at PHCs,
representing a missed opportunity for TB diagnosis. However from the study we cannot deter-
mine who actually had TB and have no way of knowing what would have happened if every
symptomatic person had been tested for TB. Testing everyone reporting a TB symptom would
be expensive especially with Xpert MTB/RIF and might not be cost effective. There is an urgent
need to identify who should be prioritised for testing among people presenting at PHC with
symptoms suggestive of TB. Reporting TB symptoms to health care workers was an important
determinant for having sputum collected for TB investigations supporting the notion that edu-
cating patients and empowering them to better report symptoms when they attend clinics
could improve investigation practices. However this needs to be done alongside better adher-
ence to investigation algorithms and emphasising to HCW that we must diagnose and treat TB
as early as possible.
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